SWTX
Price:
$36.8
Market Cap:
$2.74B
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advance...[Read more]
Industry
Biotechnology
IPO Date
2019-09-13
Stock Exchange
NASDAQ
Ticker
SWTX
According to SpringWorks Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.66B. This represents a change of -3.27% compared to the average of 2.75B of the last 4 quarters.
The mean historical Enterprise Value of SpringWorks Therapeutics, Inc. over the last ten years is 1.73B. The current 2.66B Enterprise Value has changed 15.27% with respect to the historical average. Over the past ten years (40 quarters), SWTX's Enterprise Value was at its highest in in the June 2021 quarter at 3.91B. The Enterprise Value was at its lowest in in the September 2019 quarter at -138139707.28.
Average
1.73B
Median
1.33B
Minimum
456.64M
Maximum
3.00B
Discovering the peaks and valleys of SpringWorks Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 190.74%
Maximum Annual Enterprise Value = 3.00B
Minimum Annual Increase = -54.40%
Minimum Annual Enterprise Value = 456.64M
Year | Enterprise Value | Change |
---|---|---|
2023 | 2.14B | 61.27% |
2022 | 1.32B | -54.40% |
2021 | 2.90B | -3.09% |
2020 | 3.00B | 125.64% |
2019 | 1.33B | 190.74% |
2018 | 456.64M | -52.83% |
The current Enterprise Value of SpringWorks Therapeutics, Inc. (SWTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.12B
5-year avg
2.14B
10-year avg
1.73B
SpringWorks Therapeutics, Inc.’s Enterprise Value is greater than Relay Therapeutics, Inc. (604.65M), greater than Stoke Therapeutics, Inc. (447.63M), greater than Pliant Therapeutics, Inc. (796.64M), greater than Black Diamond Therapeutics, Inc. (122.92M), greater than Arvinas, Inc. (1.19B), greater than Day One Biopharmaceuticals, Inc. (853.53M), less than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (206.29M), greater than Terns Pharmaceuticals, Inc. (220.56M), less than Apellis Pharmaceuticals, Inc. (4.20B), greater than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (7.95B), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (34.29M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Avidity Biosciences, Inc. (3.36B), less than Blueprint Medicines Corporation (6.10B), greater than Sana Biotechnology, Inc. (357.58M), greater than Kymera Therapeutics, Inc. (2.63B), greater than Monte Rosa Therapeutics, Inc. (353.40M),
Company | Enterprise Value | Market cap |
---|---|---|
604.65M | $707.19M | |
447.63M | $595.35M | |
796.64M | $816.05M | |
122.92M | $123.35M | |
1.19B | $1.27B | |
853.53M | $1.27B | |
3.91B | $4.12B | |
206.29M | $275.56M | |
220.56M | $489.39M | |
4.20B | $4.12B | |
79.12M | $58.11M | |
7.95B | $8.06B | |
-8620212.00 | $3.57M | |
34.29M | $40.76M | |
8.24B | $8.19B | |
3.36B | $3.72B | |
6.10B | $5.72B | |
357.58M | $388.49M | |
2.63B | $2.65B | |
353.40M | $435.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SpringWorks Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SpringWorks Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is SpringWorks Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for SpringWorks Therapeutics, Inc. (SWTX)?
What is the 3-year average Enterprise Value for SpringWorks Therapeutics, Inc. (SWTX)?
What is the 5-year average Enterprise Value for SpringWorks Therapeutics, Inc. (SWTX)?
How does the current Enterprise Value for SpringWorks Therapeutics, Inc. (SWTX) compare to its historical average?